UCSF School of Pharmacy

UCSF School of Pharmacy

Higher Education

San Francisco, California 1,808 followers

Science is the foundation of our innovative research, patient care, and PharmD and graduate programs.

About us

The UCSF School of Pharmacy focuses on improving health through precise therapeutics—medicines, medical devices, and diagnostic tests. Our faculty is advancing innovative therapeutics-related science, guiding the most creative PhD scientists-in-the-making, and preparing Doctor of Pharmacy (PharmD) students to think critically. We are steering the direction of research and health care delivery outside academia, working as pharmacists on health teams in groundbreaking ways, caring for patients through new approaches, and empowering patients with the information they need to make the best personal choices about medications.

Website
https://pharmacy.ucsf.edu/
Industry
Higher Education
Company size
10,001+ employees
Headquarters
San Francisco, California

Updates

  • Bringing with it new discoveries, new opportunities and even a new graduate degree program with AI at the forefront, 2024 was a year of innovation and continued excellence at the University of California, San Francisco School of Pharmacy.  Here are just a few of the many highlights that advanced our mission of leadership in research, education, clinical care, and entrepreneurship — expanding knowledge and improving the health of people everywhere.  https://lnkd.in/gtyh5AFy

    • No alternative text description for this image
    • No alternative text description for this image
  • In the world of precision medicine, molecular diagnostics (MDx) have the power to transform patient care by using genetic information to guide individualized approaches to care and improve clinical outcomes. Yet access to these advanced tests often lags their development, primarily due to cost and uneven insurance coverage. Department of Clinical Pharmacy Assistant Professor Emily A. Hammad Mrig, PhD, is tackling this issue by using AI tools to identify patients and solutions that make MDx more affordable and equitable. Read more: https://lnkd.in/gnm5pmyy

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +1
  • 🎥 Step into a day in the life of a future pharmacist! Follow Rhea M., a PharmD learner in the Class of 2026 from San Ramon, CA. She decided to pursue pharmacy as a career after working at a local pharmacy during the pandemic, administering COVID vaccines and tests. She loved the patient interaction and the ability to make a tangible difference in people’s lives. She was drawn to the way the University of California, San Francisco curriculum is structured around blocks. “I like that I’m learning everything about a system in a way that connects it all,” she said. “Like in cardio, I’m learning everything — pathophys, biochem, thermo — everything there is to know about the heart and the medications used for it.” When she’s not on campus, she works as an intern at a startup focused on AI in the pharmaceutical industry. She continues to be passionate about clinical work, and also intrigued by how AI could shape the future of pharmacy. “When I first started pharmacy school, I thought I had a clear plan,” she said, “but now I’m realizing there are so many opportunities out there.” #PharmacySchool #PharmDLife #FuturePharmacist #UCSFLife 

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +1
  • 🎥 Step into a day in the life of a future pharmacist! Follow Ashley Leong, a Doctor of Pharmacy Candidate in the Class of 2025 who is currently an Advanced Pharmacy Practice Experience (APPE) student on an inpatient cardiology rotation. Her typical day balances rounds with the cardiology team, discharge rounds, patient handoffs, and meetings with her preceptor — while also making time for vital self-care moments. See firsthand what it’s like to pursue a career transforming lives through pharmacy! 💊 #PharmacySchool #PharmDLife #FuturePharmacist #UCSFLife 

  • Congrats to PharmD students Keo Chui and Immanuel Tjahjadi, both Class of 2025, who took third place in the American Society of Health-System Pharmacists (ASHP) 29th Clinical Skills Competition. The event, which drew teams from 133 schools and colleges of pharmacy, was held at the ASHP Midyear Clinical Meeting, Dec 8-12 in New Orleans, LA. The national interactive competition challenged student pharmacists to analyze complex patient case scenarios and make treatment recommendations for them. Chui and Tjahjadi were advised by Mike Trillanes, PharmD, BCCCP, faculty advisor of UCSF’s chapter of the California Society of Health - System Pharmacists (CSHP), who helped prepare them for the team-based analysis of clinical scenarios faced by hospital and health-system pharmacists. 

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • We’re thrilled to welcome the first cohort of our new Master of Science program in Artificial Intelligence and Computational Drug Discovery and Development (AICD3). Meet our learners! Yagmur Su Oner received her BA in Cognitive Science from the University of California, Berkeley, and is also a speech and debate coach. Her research interests include the intersection of biotech and law, as well as the computational development of therapeutics for neurological, dermatological, and oncological conditions. Q: Why did you decide to apply to a program in AI and computational drug discovery? What are you most excited to learn? I’ve always been drawn to spaces where science, technology and business converge. However, this convergence also presents new legal and ethical challenges, particularly concerning intellectual property, regulatory frameworks, and patient data protection. By mastering the tools to apply AI in drug discovery, I’ll not only be able to push the boundaries of what’s possible in personalized medicine but also help navigate the legal and business complexities that come with this transformative technology. Q: How do you feel AI will help advance your research interest? AI’s ability to process vast amounts of data allows us to uncover previously hidden patterns, which could lead to breakthroughs in understanding the underlying causes of these diseases. The use of patient data to fuel these AI models for advancements in personalized medicine should not come at the cost of individual rights, so I’m looking forward to contributing to scientific progress from both a technological and ethical lens. Q: Where do you see the future of AI and health care? AI will continue to drive innovations in personalized medicine, ensuring treatments are tailored to individual genetic profiles and reshaping clinical trials by identifying ideal candidates and predicting outcomes with greater accuracy. In the long term, AI could help democratize health care by making sophisticated diagnostic tools and treatments more accessible worldwide. But the future of AI and health care is dependent on [training] a generation of future leaders who have had their technical skills nurtured, and who have the tools and knowledge to build ethical, impactful innovations. Q: What have you enjoyed most about the program so far? What I’ve enjoyed most about this program is its unique interdisciplinary approach, which brings together leading experts and students from diverse fields such as biology, computer science, engineering, and medicine. This creates an incredibly dynamic, collaborative environment where innovative ideas are constantly exchanged. #ucsf #ucsfproud

    • No alternative text description for this image
    • No alternative text description for this image
  • Recognizing University of California, San Francisco’s research excellence, several faculty members from the School have been included in the Clarivate 2024 list of Highly Cited Researchers, recognizing the significant impact of their scholarly contributions. Researchers were chosen by their authorship of multiple Highly Cited Papers—those that ranked in the top 1% of citations within their fields and publication year in the Web of Science over the past decade. The list includes:   Nevan Krogan, PhD, director of the School’s Quantitative Biosciences Institute (QBI), renowned for his work in systems pharmacology. Brian Shoichet, PhD, co-vice dean of graduate pharmacy education programs, for the field of pharmaceutical chemistry and a leader in computational drug discovery. Aashish Manglik, MD, PhD, a faculty member in the Department of Pharmaceutical Chemistry and an expert in molecular pharmacology. Kathy Giacomini, PhD, BSPharm, a leader in pharmacogenomics, drug development, and regulatory sciences and the School’s dean. Of all the world’s scientists and social scientists, Highly Cited Researchers are 1 in 1,000. This recognition reflects the school’s commitment to fostering groundbreaking research that addresses critical issues in health care and pharmaceutical sciences. 

    • No alternative text description for this image
  • Dr. Robert Califf, the 25th Commissioner of the FDA and a distinguished leader in healthcare innovation, will be honored at Precision Medicine World Conference (PMWC) 2025 with the prestigious Pioneer Award. Following the award ceremony 🗓️ on February 5th, 🗓️ join us for an exclusive fireside chat with Dr. Califf, Keith R. Yamamoto, and Kathy Giacomini, University of California, San Francisco. This engaging discussion will delve into the future of healthcare innovation, AI applications, and regulatory advancements shaping the industry. https://lnkd.in/gNXepUXj

    View profile for Tal Behar, graphic

    Co-founder & President, PMWC Intl / 33,000 LI Followers / PMWC Newsletters 92,000+ subscribers since 2009- SORRY, UNABLE TO ACCEPT MORE CONNECTIONS DUE TO THE LINKEDIN LIMIT

    Saluting and Honoring Dr. Robert Califf’s Visionary Leadership in Innovation and Healthcare at PMWC 2025 (Feb. 5-7). Dr. Robert Califf, the 25th Commissioner of the FDA and a distinguished leader in healthcare innovation, will be honored at PMWC 2025 with the prestigious Pioneer Award. Before resuming his role at the FDA, Dr. Califf served as Chief Medical Officer at Verily, where he spearheaded groundbreaking initiatives in precision health and data-driven healthcare solutions. His leadership at Verily highlighted his dedication to advancing patient care through technological innovation. At PMWC 2025, we celebrate Dr. Califf for his transformative contributions, which include: --Pioneering AI-Driven Regulatory Guidance: Developing guidelines for the safe and effective use of AI in drug manufacturing. --Modernizing Regulatory Frameworks: Adapting FDA regulations to keep pace with rapid technological advancements. --Fostering Innovation: Encouraging the development of innovative medical products while ensuring patient safety. His work exemplifies a balance between fostering innovation and maintaining rigorous safety standards, ensuring that advancements in healthcare delivery are both groundbreaking and secure. Following the award ceremony on February 5th, join us for an exclusive fireside chat with Dr. Califf, Keith R. Yamamoto, and Kathy Giacomini, UCSF. This engaging discussion will delve into the future of healthcare innovation, AI applications, and regulatory advancements shaping the industry. Don’t miss this opportunity to celebrate and learn from one of the most influential leaders in healthcare. Join us in congratulating him: Duke University, Duke Clinical Research Institute, RALPH SNYDERMAN, M.D.. Geoffrey Ginsburg, Susan Winckler, Reagan-Udall Foundation for the FDA, Mei Sheng Duh, RPh, MPH, ScD, Analysis Group, Rachael Fones, Sheila D. Walcoff, JD. Critical Path Institute (C-Path), Ida Sim, Sharat Israni, Erin Rainaldi, Andrew Trister, MD PhD, Charles Gersbach, Susan Lynch, Olivier Gevaert, Michelle Arkin, , Advanced Research Projects Agency for Health (ARPA-H), Chuck Romine, National Institute of Standards and Technology (NIST), Erwin Gianchandani, National Science Foundation (NSF), Nooshin Navidi Latour Sam Sinai, Dyno Therapeutics, Namrata A., Diffuse Bio, Rishi Bedi, Y-Trap Jianying Hu, IBM, Portola Pharmaceuticals, Regado BioSciences, Inc., PMWC - Precision Medicine World Conference See Track 4 Feb. 5th: https://lnkd.in/gPtkWZbQ

    • No alternative text description for this image

Affiliated pages

Similar pages